KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Common Equity (2020 - 2025)

Historic Common Equity for AbCellera Biologics (ABCL) over the last 6 years, with Q3 2025 value amounting to $964.0 million.

  • AbCellera Biologics' Common Equity fell 1057.94% to $964.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $964.0 million, marking a year-over-year decrease of 1057.94%. This contributed to the annual value of $1.1 billion for FY2024, which is 835.13% down from last year.
  • Latest data reveals that AbCellera Biologics reported Common Equity of $964.0 million as of Q3 2025, which was down 1057.94% from $1.0 billion recorded in Q2 2025.
  • In the past 5 years, AbCellera Biologics' Common Equity registered a high of $1.3 billion during Q3 2022, and its lowest value of $953.4 million during Q3 2021.
  • Its 5-year average for Common Equity is $1.1 billion, with a median of $1.1 billion in 2024.
  • Per our database at Business Quant, AbCellera Biologics' Common Equity surged by 3112.82% in 2022 and then plummeted by 1057.94% in 2025.
  • Quarter analysis of 5 years shows AbCellera Biologics' Common Equity stood at $1.0 billion in 2021, then grew by 20.23% to $1.2 billion in 2022, then decreased by 6.56% to $1.2 billion in 2023, then fell by 8.35% to $1.1 billion in 2024, then fell by 8.72% to $964.0 million in 2025.
  • Its last three reported values are $964.0 million in Q3 2025, $1.0 billion for Q2 2025, and $1.0 billion during Q1 2025.